Patents Represented by Attorney Leanne C. Incyte Pharmaceuticals, Inc. Price
-
Patent number: 6143544Abstract: The invention provides a new human lysophospholipase (JHLP) and polynucleotides which identify and encode IHLP. The invention also provides expression vectors, host cells, agonists, antibodies and antagonists. The invention also provides methods for treating inflammation and disorders associated with expression of IHLP.Type: GrantFiled: June 19, 1997Date of Patent: November 7, 2000Assignee: Incyte Pharmaceuticals, Inc.Inventors: Jennifer L. Hillman, Purvi Shah, Neil C. Corley, Lynn E. Murry
-
Patent number: 6136955Abstract: The present invention provides a human SMT3-like protein (HSMTH) and polynucleotides which identify and encode HSMTH. The invention also provides expression vectors, host cells, agonists, antibodies and antagonists. In addition, the invention provides methods for producing HSMTH and for treating or preventing disorders associated with expression of HSMTH.Type: GrantFiled: October 14, 1998Date of Patent: October 24, 2000Assignee: Incyte Pharmaceuticals, Inc.Inventors: Jennifer L. Hillman, Purvi Shah
-
Patent number: 6090377Abstract: The present invention provides novel monocyte activating cytokine (MAC) and a polynucleotide encoding MAC. The invention also provides for genetically engineered expression vectors and host cells comprising the nucleic acid sequence encoding MAC. The invention also provides for the production and use of substantially purified MAC in pharmaceutical compositions for the treatment of cancer and disease of the immune system. The invention also describes diagnostic assays which utilize the polynucleotide to hybridize with the transcripts encoding MAC and antibodies which specifically bind to MAC.Type: GrantFiled: July 28, 1998Date of Patent: July 18, 2000Assignee: Incyte Pharmaceuticals, Inc.Inventors: Olga Bandman, Roger Coleman, Janice Au-Young, Lynn E. Murry
-
Patent number: 6074844Abstract: The invention provides two new human membrane fusion proteins (SYTAX1 or SYTAX2) and polynucleotides which identify and encode SYTAX1 or SYTAX2. The invention also provides expression vectors, host cells, agonists, antibodies and antagonists. The invention also provides methods for treating disorders associated with expression of SYTAX1 or SYTAX2.Type: GrantFiled: June 11, 1997Date of Patent: June 13, 2000Assignee: Incyte Pharmaceuticals, Inc.Inventors: Jennifer L. Hillman, Preeti Lal, Neil C. Corley
-
Patent number: 6033893Abstract: The invention provides a new human cathepsin (LCAP) and polynucleotides which identify and encode LCAP. The invention also provides expression vectors, host cells, agonists, antibodies and antagonists. The invention also provides methods for treating disorders associated with expression of LCAP.Type: GrantFiled: June 26, 1997Date of Patent: March 7, 2000Assignee: Incyte Pharmaceuticals, Inc.Inventors: Olga Bandman, Karl J. Guegler, Neil C. Corley, Purvi Shah
-
Patent number: 6025464Abstract: The invention provides two new WD-40 proteins (WDPro) and polynucleotides which identify and encode WDPro. The invention also provides expression vectors, host cells, agonists, antibodies and antagonists. The invention also provides methods for treating disorders associated with expression of WDPro.Type: GrantFiled: December 2, 1998Date of Patent: February 15, 2000Assignee: Incyte Pharmaceutials, Inc.Inventors: Olga Bandman, Preeti Lal, Neil C. Corley
-
Patent number: 6018028Abstract: The present invention provides polynucleotides which identify and encode novel human proteasome subunit proteins. The invention provides for genetically engineered expression vectors and host cells comprising the nucleic acid sequences encoding PSUB. The invention also provides for the use of substantially purified PSUB, antagonists, and in pharmaceutical compositions for the treatment of diseases associated with the expression of PSUB. Additionally, the invention provides for the use of antisense molecules to PSUB in pharmaceutical compositions for treatment of diseases associated with the expression of PSUB. The invention also describes diagnostic assays which utilize diagnostic compositions comprising the polynucleotide, fragments or the complement thereof, which hybridize with the genomic sequence or the transcript of polynucleotides encoding PSUB or anti-PSUB antibodies which specifically bind to PSUB.Type: GrantFiled: August 13, 1998Date of Patent: January 25, 2000Assignee: Incyte Pharmaceuticals, Inc.Inventors: Olga Bandman, Janice Au-Young, Jennifer L. Hillman, Surya K. Goli
-
Patent number: 6015672Abstract: The invention provides a human Rab-specific guanine-nucleotide dissociation inhibitor (RGDI) and polynucleotides which identify and encode RGDI. The invention also provides expression vectors, host cells, agonists, antibodies and antagonists. The invention also provides methods for treating disorders associated with expression of RGDI.Type: GrantFiled: December 3, 1997Date of Patent: January 18, 2000Assignee: Incyte Pharmaceuticals, Inc.Inventors: Henry Yue, Neil C. Corley, Preeti Lal
-
Patent number: 5998373Abstract: The invention provides a human carboxypeptidase inhibitor (CARIN) and polynucleotides which identify and encode CARIN. The invention also provides expression vectors, host cells, agonists, antibodies and antagonists. The invention also provides methods for treating disorders associated with expression of CARIN.Type: GrantFiled: December 15, 1998Date of Patent: December 7, 1999Assignee: Incyte Pharmaceuticals, Inc.Inventors: Jennifer L. Hillman, Preeti Lal
-
Patent number: 5986064Abstract: The present invention provides a human tumor-associated Kazal inhibitor (HuKI) and polynucleotides which identify and encode HuKI. The invention also provides expression vectors, host cells, antibodies and antagonists. The invention also provides methods for the prevention and treatment of diseases associated with expression of HuKI, as well as diagnostic assays.Type: GrantFiled: December 3, 1998Date of Patent: November 16, 1999Assignee: Incyte Pharmaceuticals, Inc.Inventors: Olga Bandman, Karl J. Guegler, Purvi Shah
-
Patent number: 5976528Abstract: The present invention provides a human glutathione S-transferase (HGST) and polynucleotides which identify and encode HGST. The invention also provides genetically engineered expression vectors and host cells comprising the nucleic acid sequences encoding HGST and a method for producing HGST. The invention also provides for agonists, antibodies, or antagonists specifically binding HGST, and their use, in the prevention and treatment of cancer and other diseases associated with the expression of HGST. Additionally, the invention provides for the use of antisense molecules to polynucleotides encoding HGST for the treatment of cancer and other diseases associated with the expression of HGST. The invention also provides diagnostic assays which utilize the polynucleotide, or fragments or the complement thereof, and antibodies specifically binding HGST.Type: GrantFiled: June 12, 1998Date of Patent: November 2, 1999Assignee: Incyte Pharmaceuticals, Inc.Inventors: Surya K. Goli, Jennifer L. Hillman
-
Patent number: 5976801Abstract: The invention provides two human reticulocalbin isoforms designated individually as RCN .gamma. and RCN .delta. and collectively as RCN, and polynucleotides which identify and encode RCN. The invention also provides expression vectors, host cells, agonists, antibodies and antagonists. The invention also provides methods for treating disorders associated with expression of RCN.Type: GrantFiled: August 8, 1997Date of Patent: November 2, 1999Assignee: Incyte Pharamceuticals, Inc.Inventors: Olga Bandman, Jennifer L. Hillman, Preeti Lal, Neil C. Corley, Purvi Shah
-
Patent number: 5955305Abstract: The present invention provides a human retinoid binding protein (Hu-RBP) and polynucleotides which identify and encode Hu-RBP. The invention also provides expression vectors, host cells, antibodies and antagonists. The invention also provides methods for the prevention and treatment of diseases associated with expression of Hu-RBP, as well as diagnostic assays.Type: GrantFiled: April 28, 1997Date of Patent: September 21, 1999Assignee: Incyte Pharmaceuticals, Inc.Inventors: Olga Bandman, Preeti Lal, Joanne R. Petithory
-
Patent number: 5952177Abstract: The invention provides a human cytosolic isocitrate dehydrogenase (HCID) and polynucleotides which identify and encode HCID. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for treating disorders associated with expression of HCID.Type: GrantFiled: December 3, 1997Date of Patent: September 14, 1999Assignee: Incyte Pharmaceuticals, Inc.Inventors: Olga Bandman, Preeti Lal, Neil C. Corley, Janice Au-Young
-
Patent number: 5948641Abstract: The present invention provides a metal response element binding protein (MERESP) and polynucleotides which identify and encode MERESP. The invention also provides expression vectors, host cells, agonists, antibodies, and antagonists. The invention also provides methods for treating disorders associated with expression of MERESP.Type: GrantFiled: May 29, 1997Date of Patent: September 7, 1999Assignee: Incyte Pharmaceuticals, Inc.Inventors: Preeti Lal, Purvi Shah, Neil C. Corley
-
Patent number: 5942399Abstract: The invention provides a human amino acid permease homolog (AAPH) and polynucleotides which identify and encode AAPH. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for diagnosing, treating or preventing disorders associated with expression of AAPH.Type: GrantFiled: May 6, 1998Date of Patent: August 24, 1999Assignee: Incyte Pharmaceuticals, Inc.Inventors: Jennifer L. Hillman, Henry Yue, Neil C. Corley
-
Patent number: 5935812Abstract: The present invention provides a polynucleotide which identifies and encodes a novel human GTP binding protein gamma-3 (HGPG) and HGPG itself. The invention provides for genetically engineered expression vectors, host cells containing the vector and a method for producing HGPG. The invention also provides a method for identifying pharmaceutical compositions inhibiting the expression and activity of HGPG and for the use of such compositions for the treatment of cancer. The invention also provides diagnostic assays which utilize the polynucleotide to hybridize with the transcripts encoding HGPG or anti-HGPG antibodies which specifically bind to HGPG in normal or diseased tissues.Type: GrantFiled: September 18, 1996Date of Patent: August 10, 1999Assignee: Incyte Pharmaceuticals, Inc.Inventors: Olga Bandman, Surya K. Goli, Lynn E. Murry
-
Patent number: 5935813Abstract: The present invention provides a novel human C-type lectin (human PAP-2) and polynucleotides which identify and encode human PAP-2. The invention also provides expression vectors, host cells, agonists, antibodies or antagonists. The invention also provides methods for treating or preventing diseases associated with expression of human PAP-2.Type: GrantFiled: March 20, 1997Date of Patent: August 10, 1999Assignee: Incyte Pharmaceuticals, Inc.Inventors: Jennifer L. Hillman, Surya K. Goli
-
Patent number: 5928923Abstract: The invention provides a human short-chain dehydrogenase (HSCD) and polynucleotides which identify and encode HSCD. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for treating or preventing disorders associated with expression of HSCD.Type: GrantFiled: February 5, 1998Date of Patent: July 27, 1999Assignee: Incyte Pharmaceuticals, Inc.Inventors: Preeti Lal, Neil C. Corley
-
Patent number: 5919655Abstract: The present invention provides a human phospholemman homolog protein (HPLMH) and polynucleotides which identify and encode HPLMH. The invention also provides genetically engineered expression vectors and host cells comprising the nucleic acid sequences encoding HPLMH. The invention also provides for the use of HPLMH, and antibodies, or agonists or antagonists specifically binding HPLMH, in the prevention and treatment of diseases associated with expression of HPLMH. Additionally the invention provides for the use of antisense molecules to polynucleotides encoding HPLMH for the treatment of diseases associated with the expression of HPLMH. The invention also provides diagnostic assays which utilize the polynucleotide, or fragments or the complement thereof, and antibodies specifically binding HPLMH.Type: GrantFiled: October 25, 1996Date of Patent: July 6, 1999Assignee: Incyte Pharmaceuticals, Inc.Inventors: Olga Bandman, Jennifer L. Hillman